financetom
Business
financetom
/
Business
/
Real estate welcomes the overdue repo rate cut by RBI
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Real estate welcomes the overdue repo rate cut by RBI
Feb 7, 2019 3:32 AM

The Reserve Bank of India's (RBI) decision to slash the repo rate by 25 basis point to 6.25 percent is a welcome and unexpectedly positive move, given the sops that the recent expansionary budget gave to farmers at an additional cost of Rs 75,000 crore per annum.

It was also overdue, as this has been the first cut in a long time. It definitely augurs well for the real estate sector, which also received a budget bonanza in the previous week.

Rate cuts give a substantial push to property buyer sentiments, and it was certainly high time for such a cut. Home loan interest rates increased by as much as 5-7 percent in the last one year as the RBI hiked its repo rates by 50 basis points over the same period. In other words, home loans had become a more expensive proposition.

However, the real estate market does not depend only on marginally improved buyer sentiment - there are larger issues that hold the sector hostage right now. The liquidity issues post the non-banking finance company (NBFC) crisis are a bigger concern. NBFCs and housing finance companies (HFCs) have seriously curtailed disbursements to developers. Moreover, the repayment capabilities of many developers are also in question.

Furthermore, though the account deficit (CAD) widened to 2.9 percent in December, inflation targets are more or less within control and the GDP is estimated to grow at a very healthy 7.5 percent in the new fiscal. Going by these indicators, the Indian economy is looking at a good financial year ahead - always assuming that a stable government is voted to power in the upcoming general elections.

Anuj Puri is the chairman of ANAROCK Property Consultants.

First Published:Feb 7, 2019 12:32 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Walmart to cut 1,500 jobs to lower expenses, WSJ reports
Walmart to cut 1,500 jobs to lower expenses, WSJ reports
May 26, 2025
(Reuters) -Retail bellwether Walmart ( WMT ) plans to cut about 1,500 jobs as part of a restructuring plan to lower expenses, the Wall Street Journal reported on Wednesday, citing a person familiar with the matter. The company's plan will impact teams in its global technology operations, e-commerce fulfillment in U.S. stores, and its advertising business Walmart Connect, the report...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
PROREIT Declares May Distribution
PROREIT Declares May Distribution
May 26, 2025
05:11 PM EDT, 05/21/2025 (MT Newswires) -- Pro Real Estate Investment Trust (PRV-UN.TO) on Wednesday declared a cash distribution of $0.0375 per trust unit of the REIT for the month of May ($0.45 on an annualized basis) will be payable on June 16 to unitholders of record as at May 30. This is consistent with the April distribution. ...
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis
May 26, 2025
05:10 PM EDT, 05/21/2025 (MT Newswires) -- Insmed ( INSM ) said Wednesday that brensocatib, its investigational dipeptidyl peptidase-1 inhibitor for non-cystic fibrosis bronchiectasis, demonstrated consistent efficacy and safety across three prespecified subgroups in the phase 3 Aspen trial. The subgroup analyses included adolescents, patients on macrolide therapy, and those with varying blood eosinophil levels. The data showed brensocatib reduced...
Copyright 2023-2026 - www.financetom.com All Rights Reserved